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Multiple Sclerosis (MS) affects 400,000 people in 
the USA and almost 2.5 million people worldwide. 
There is no cure for MS. A variety of disease-modifying 
therapies are currently available. They aim to reduce 
disease activity that ultimately leads to disability. 
However, such drugs have adverse effects that vary 
widely among patients making the choice of a suitable 
drug particularly challenging. With the proliferation of 
social media, this research aims to understand the 
perspective of people with MS on social media (Twitter) 
in regard to Adverse Drug Events (ADEs) and to 
analyze ADEs as perceived by MS patients. This study 
helps in understanding ADEs associated with MS drugs 
and can further inform future medical research by 
highlighting and prioritizing additional clinical trials 
needed to better assess such adverse drug effects.  
1. Introduction  
Multiple Sclerosis (MS) is considered to be an 
immune-meditated disease that occurs when the 
immune system attacks the central nervous system 
(CNS). The immune system’s attack damages myelin, 
oligodendrocytes, and underlying nerve fibers, 
impairing the ability of the CNS to send or receive 
messages [1]. The most unsettling aspect of MS is that 
its cause is still not clear. Based on the clinical criteria, 
frequency of clinical relapses, time taken for disease 
progression, and lesion development as shown by MRI 
findings, MS is classified into four types, namely 
Relapsing-remitting MS (RRMS), Secondary 
Progressive MS (SPMS), Primary progressive MS 
(PPMS) and Clinically Isolated Syndrome (CIS). 
Almost 85% of people having MS fall under RRMS, 
which is characterized by relapses followed by periods 
of complete or partial recovery [2]. Some early signs 
and symptoms of MS include tingling and numbness, 
optic neuritis, fatigue, pain, muscle spasm and 
weakness, balance problems, bladder issues, cognitive 
difficulties, depression, and anxiety. MS patients are 
prescribed disease-modifying drugs to delay 
neurological disability progression [3], [4]. 
ADEs are unfavorable and unintentional signs or 
symptoms associated with the use of a medication [5]. 
The Center for Disease Control (CDC) advises adults to 
follow precautions to reduce the risk of ADEs by 
keeping a list of their medications, following directions, 
asking questions, keeping up with any blood testing 
recommended by the doctor, and taking all the 
medicines strictly as directed. The burden of ADEs to 
the nation’s economy is estimated at $30.1 billion 
annually [6]. Prescription drugs for MS are known to 
result in a variety of adverse effects, some of which are 
very serious. While many of these adverse effects are 
reported in the literature, their extent varies substantially 
among MS patients making it particularly challenging 
to identify a suitable drug for a particular patient. This 
is also a recurring problem as patients often need to 
switch medications during the course of treatment. 
With the proliferation of social media, health 
became a prevalent topic that people discuss on these 
platforms [7]. Today, social media has evolved as a 
fertile platform for patients to exchange information 
regarding their experiences with a life-changing 
condition such as MS. This includes sharing information 
about symptoms, disease progression, and adverse drug 
effects. Such wealth of information creates 
opportunities for healthcare professionals and 
researchers to gain further insights into various disease 
conditions as they relate to symptoms, adverse drug 
effects and experiences.  
A few studies have proposed ADE detection 
methods utilizing social media data [8]. These social 
media platforms can be patient discussion forums or 
social networking platforms such as Facebook and 
Twitter. To the best of our knowledge, there are only 
two studies that utilized social media data for assessing 
patterns and sentiments regarding MS treatments. One 
exploratory study investigated opinions regarding MS 







treatments and found that oral MS treatments tend to 
show higher sentiment scores than injectable treatments 
[9], while another study explored patterns of treatment 
switching by MS patients [10].  
Accordingly, in this research, we complement prior 
research by extracting prevalent MS ADEs as reported 
on social media (Twitter). Further, we conduct a 
sentiment analysis that provides a holistic perspective of 
patients’ perception of various drugs given their side 
effects. The analysis covers 18 different MS drugs and 
leverages text mining to quantify the volume and 
sentiments of the ensuing discussion, and to capture the 
dominant ADEs categories for each drug. Overall, this 
sheds light on the safety and effectiveness of drugs used 
for MS treatment. The outcome can help patients and 
clinicians identify appropriate courses of action. 
Further, the results can inform future medical research 
by highlighting and prioritizing additional clinical trials 
needed to better understand such adverse drug effects.  
The remainder of the paper is organized as follows: 
Section 2 provides a brief review of related work while 
section 3 describes the research methodology. Section 4 
presents the results obtained while section 5 includes an 
interpretation and discussion of our findings with 
reference to extant research. Section 6 concludes by 
summarizing the research and discussing the limitations 
and research scope for the future. 
2. Related work 
ADEs post-marketing surveillance can rely on 
different types of data obtained from various sources 
[11] such as Electronic Health Records (EHR), and 
voluntarily reported data on such systems as the Food 
and Drug Administration’s (FDA) Adverse Event 
Reporting System (FAERS) [12]. However, these 
sources could suffer from low reporting rates and 
limited scope. Accordingly, a number of studies utilized 
social media platforms as a source potentially offering a 
relatively broad and timely data to understand and 
address health-related issues [13], [14]. Of particular 
interest to the medical informatics research community 
is leveraging social medial to monitor ADEs [8]. For 
example, a few studies [15]–[18] used Twitter to detect 
and track ADEs while other studies relied on healthcare 
social media forums [19], [20]. Some studies on ADEs 
proposed and implemented near real-time pipelines and 
models for ADE detection and prediction [18], [21].  
ADEs studies utilized a variety of techniques such as but 
not limited to; association rule mining [20], natural 
language processing (NLP) and deep learning [22], 
extracting deep linguistic features [23], ensemble 
classification [24], statistical modeling [25], and topic 
modeling.  
With respect to MS, one study used an exploratory 
approach to analyze sentiments pertaining to MS 
treatments using twitter data [9]. The study identified 
tweets mentioning MS treatments and used them to 
analyze patients’ sentiments. The study conducted in 
2014 did not analyze adverse effects nor did it include a 
number of now available newer medications. Another 
study used automated listening with filtering and 
analysis of data to examine the patterns of treatment 
switching between infectable, oral, and infusion 
therapies for MS patients [10]. Accordingly, this study, 
complement prior research by focusing on the ADEs of 
MS treatments from user contributed contents, namely 
Twitter, as well as further exploring patients’ sentiments 
towards MS medications on a wider selection of these 
drugs. 
3. Methodology 
We followed the pipeline in Figure 1 for performing 
this research. The pipeline included four stages: data 
discovery, data collection, data preparation, and data 
analysis. We employed Crimson Hexagon (CH) (now 
Brandwatch) to understand the public’s perspective on 
MS treatments and ADEs. CH is an AI-powered 
consumer insights tool used to scrape data from social 
media and analyze it for insights. It is a social media 
analytics tool that utilizes machine learning and text 
mining approaches developed by the founder of CH 
[26]. 
 




The Data discovery stage consisted of creating a 
Boolean search query for CH using the drug names. The 
search query was limited to tweets in the English 
language, from 1 Jan 2010 to 1 Jan 2020. The MS 
treatments considered for this study were Avonex, 
Betaseron, Copaxone, Glatiramer Acetate, Extavia, 
Glatopa, Plegridy, Rebif, Aubagio, Gilenya, 
Mavenclad, Mayzent, Tecfidera, Vumerity, Lemtrada, 
Novantrone, Ocrevus, and Tysabri. We standardized the 
search based on the brand names of the drugs, as some 
of the active ingredients (generic name) are indicated for 
other conditions. CH search query employed case 
insensitive approach for searching the tweets. 
In the data collection stage, the search query 
retrieved the required data from CH for manual 
examination for relevant posts. The retrieved data for all 
the drugs was examined particularly for unusually high 
volume of tweets on a particular day or time period to 
help us redefine the inclusion and exclusion criteria in 
the data discovery stage. This examination of tweets was 
manually done. Overall, we found that there was quite 
an unusual activity due to retweets. Further, tweets 
containing hyperlinks were considered to be irrelevant 
as they often link to advertisement or news articles about 
a particular medication rather than the patients’ 
experience. Tweets with a stock market symbols of 
pharmaceutical companies were excluded. Ultimately, 
we developed the search query template shown below: 
 
(“Drug Brand Name 1” OR “Drug Brand Name 2” 
OR “Drug Brand Name 3” OR ………….) 
AND – (http* OR RT) 
AND – (Merck OR Sereno OR Pfizer OR Biogen 
OR Bayer OR Novartis OR Teva OR Momenta OR 
Sandoz OR Sanofi OR Genentech OR "Roche 
Group") 
 
Search queries for some drugs had to be customized 
based on examining the tweets related to the drugs 
respectively. For example, we found a Twitter handle 
named ‘@aubagio’. However, there was no relation to 
MS for tweets coming from this handle.  
Once the finalized query was run in CH, we 
proceeded to the data analysis stage. We analyzed the 
results for each drug tweets by excluding references to 
other drugs to make sure each tweet reflects only one 
medication. Although some tweets comparing different 
medications would be lost, it was the best way to make 
sure we performed a valid analysis on each drug. We 
analyzed the sentiments and emotions towards MS 
treatment using the pre-trained classifier in CH. We 
employed the ReadMe algorithm [26] to analyze the 
posts that fall into predefined categories representing 
various adverse drug effects. The MS ADEs predefined 
categories follow the list of common side effects defined 
by the National MS Society for each drug. The ReadMe 
algorithm is appropriate when the objective of the study 
is to categorize the posts into a pre-defined number of 
categories and calculate the proportion of posts in each 
category [26]. This provides unbiased categorization 
and proportions even when the customized classifier 
performs poorly.  
4. Results  
A total of 51,362 unique tweets mentioned MS 
treatments after removing the tweets containing 
manufacturer or company names and hyperlinks. 
Overall, 16% of the tweets included age identification, 
while 65% identified gender. The available 
demographics of tweets are shown in Figure 2.  
 
Figure 2a. Distribution of tweets by age group 
 
Figure 2b. Distribution of tweets by gender 
We utilized pre-trained sentiment categories 
(Positive, Negative and Neutral) in CH to detect a 
tweet’s sentiment and categorize it into one of the 
sentiment categories. Similarly, we employed the pre-
defined emotion categories (Joy, Sadness, Disgust, 
Anger, Surprise, Fear and Neutral) in CH to classify the 
posts into one of the emotion categories. Figure 3 shows 
the sentiment and emotion proportions of the tweets for 
all drugs. At the same time, the emotion analysis shows 
that 37% of the tweets are neutral and followed by Joy, 
Anger, Fear, Sadness, Disgust and Surprise. 
Table 1 illustrates the tweet distribution for each 
drug, along with the sentiment proportions. With 
exclusion criteria refers to searching for a particular 
drug and excluding reference to all other drug names, 
while without exclusion criteria refer to searching for a 
particular drug and not excluding reference to all other 
drug names. Overall, the sentiment proportions for 




approximately very similar. Extavia and Tysabri had the 
highest positive sentiment proportion. Rebif and 
Avonex had the highest negative sentiment proportion. 
Copaxone, Ocrevus, Tysabri, Lemtrada, Plegridy, 
Gilenya, Mayzent and Extavia had slightly more 




Figure 3. Sentiment and emotion distribution 
of tweets 
Figure 4 depicts the distribution of tweets over time 
for MS treatments. The distribution results are similar to 
the study by Ramagopalan et al. [9] for that specific time 
period. The relative proportion of the adverse effects for 
each drug is shown in Figure 5. Adverse events for 
Avonex, Betaseron, Extavia, Rebif, and Plegridy were 
quite similar, as these medications have the same active 
ingredient, “Interferon Beta”. More than 50% of 
Aubagio’s side effects were attributed to diarrhea, hair 
loss/thinning, and liver problems. More than 61% of 
Copaxone side effects were attributed to injection site 
problems and shortness of breath.  
Liver problems alone contributed to 45% of 
Gilenya’s side effects. Liver problems, low white blood 
cells, and flu/fever/body aches accounted for 68% of 
interferon-beta’s side effects. Headache, rashes, and 
kidney problems contributed to 64% of the Lemtrada’s 
side effects. Mavenclad’s side effects were mostly 
attributed to hair loss/thinning (30%), low white blood 
cell count (25%), mouth sores and/or shingles (25%), 
and rashes (21%). Headache and low heart rate 
constituted 58% of Mayzent’s side effects. Novantrone 
side effects were caused by skin rash/reactions (75%), 
and infections (25%). Ocrevus’s side effects were 
mainly itchy skin (40%), rash (33%), and throat 
irritation (27%). Hot flushes and nausea contributed to 
65% of Tecfidera’s side effects. Headache and dizziness 
contributed to 56% of Tysabri’s side effects. 
 















Positive Negative Neutral Positive Negative Neutral	
Aubagio 1,156 1,526 0.282 0.358 0.360 0.280 0.371 0.350 
Avonex 3,945 5,099 0.340 0.361 0.300 0.333 0.367 0.300 
Betaseron 910 1,303 0.245 0.325 0.430 0.259 0.331 0.410 
Copaxone 8,733 10,421 0.340 0.330 0.330 0.342 0.348 0.310 
Extavia 265 324 0.668 0.112 0.220 0.595 0.155 0.250 
Gilenya 5,007 5,969 0.315 0.255 0.430 0.319 0.281 0.400 
Lemtrada 3,512 4,009 0.374 0.306 0.320 0.368 0.312 0.320 
Mavenclad 234 293 0.345 0.345 0.310 0.363 0.337 0.300 
Mayzent 41 53 0.300 0.250 0.450 0.348 0.212 0.440 
Novantrone 79 105 0.105 0.235 0.660 0.146 0.264 0.590 
Ocrevus 2,430 2,912 0.364 0.326 0.310 0.362 0.338 0.300 
Plegridy 333 450 0.333 0.297 0.370 0.314 0.316 0.370 
Rebif 4,376 5,383 0.318 0.372 0.310 0.321 0.379 0.300 
Tecfidera 4,881 5,958 0.338 0.352 0.310 0.337 0.363 0.300 
Tysabri 10,760 12,365 0.430 0.310 0.260 0.419 0.321 0.260 
Vumerity 15 24 0.200 0.200 0.600 0.220 0.220 0.560 
















5. Discussion  
Based on the available demographics shown in 
Figure 2, women tweeted more about MS treatments 
compared to men. People who were older than 35 
years tweeted more compared to other age groups. 
According to the National Multiple Sclerosis Society, 
MS is three time more common among women and 
most patients are diagnosed between the ages of 20 
and 50 years [27].  
The sentiment analysis in this study is consistent 
with Ramagopalan et al. [9]. The findings of the 
discovered sentiment scores from Table 1 show that 
treatments such as Extavia, Gilenya, Lemtrada, 
Mayzent, Ocrevus, and Tysabri have higher positive 
than negative tweet proportions. Extavia is the only 
injectable treatment in this category. Lemtrada, 
Tysabri, and Ocrevus are infusion treatments, while 
Gilenya and Mayzent are oral treatments. Mavenclad 
and Tecfidera, both oral treatments, appear to have a 
neutral sentiment among the public. Vumerity is new 
to the market and limited data is available for it. Based 
on the tweets and sentiment analysis, Aubagio, an oral 
drug, has a substantial negative sentiment due to the 
side effects associated with it.  
With respect to the distribution of tweets over 
time (figure 4), the tweets volume for each treatment 
shows spikes at various time points. Further 
investigation into the Twitter corpus revealed that 
spikes in the tweet volume coincide with news 
regarding the FDA approval of new MS drugs. Each 
treatment’s sentiment scores clearly show a positive 
intent and excitement for newer treatments that hit the 
market. Most of the treatments have word clusters 
related to social support and symptoms associated with 
the treatments. For instance, the word clusters for 
Extavia have “Cost” as the frequent word, and the 
other words in the clusters are “iPhone” and related 
terms. When the tweet corpus for Extavia was further 
investigated, it revealed an interesting story: people 
compare the cost of Extavia treatment to that of iPhone 
revealing the public discourse on the soaring cost of 
MS drugs. The finding is in accordance with an 
existing concern over the high pricing of MS specialty 
medications [28], [29].  
To the best of our knowledge, we present here the 
first analysis on the proportion of ADEs for each MS 
treatment. The discovered symptoms and ADEs are 
mapped to the valence of tweets for each treatment as 
summarized in Figure 5. Adverse events for Avonex, 
Betaseron, Extavia, Rebif, and Plegridy were quite 
similar, as these medications have the same active 
ingredient, “Interferon Beta”. Liver problems, low 
white blood cells, and flu/fever/body aches 
contributed to 68% of interferon-beta’s side effects. 
Nearly two-thirds (61%) of Copaxone’s side effects 
were caused by injection-site reactions and shortness 
of breath. The findings are generally consistent with 
the listed side effects [30] for this group of 
medications. Although flu-like symptoms and 
injection-site reactions are listed among the most 
common side effects [31] for interferon- beta, they 
made up only 17% and 9% respectively of discussed 
ADEs. One explanation is that patients focused on the 
more serious side effect of liver problems (34%) in 
their tweets. 
In the oral medication group, slightly more than 
half (51%) of Aubagio’s side effects were attributed to 
diarrhea, hair loss/thinning, and liver problems. Liver 
problems alone accounted for nearly half (45%) of 
Gilenya’s side effects. Hot flushes and nausea 
contributed to 65% of Tecfidera’s side effects. 
Mavenclad side effects were primarily attributed to 
hair loss/thinning (30%), low white blood cell count 
(25%), mouth sores and/or shingles (25%), and rashes 
(21%). Headache and low heart rate constituted 58% 
of Mayzent’s side effects. The findings for the oral 
group were mostly consistent with the listed side 
effects of the included medications [30]. However, 
Mavenclad, an oral immunosuppressant that is 
generally indicated to patients who have had an 
inadequate response or could not tolerate one or more 
MS therapies, had markedly fewer discussed ADEs as 
compared to the listed side effects [32], [33]. This can 
be explained by the recent FDA approval for the 
medication as well as its being a less commonly 
prescribed one, which could have affected data 
availability.  
In the infusion medications group, headache, 
rashes, and kidney problems contributed to 64% of 
Lemtrada’s side effects. Novantrone side effects were 
caused by skin rash/reactions (75%), and infections 
(25%). Ocrevus’s side effects were mainly itchy skin 
(40%), rash (33%), and throat irritation (27%). 
Headache and dizziness contributed to 56% of 
Tysabri’s side effects. The adverse events such as 
Progressive multifocal leukoencephalopathy (PML) 
are discussed in tweets related to Tysabri. Most of the 
tweets that talk about PML usually discuss the risk of 
a dangerous brain infection, contributing to fear and 
panic. The risk of PML with Tysabri can be addressed 
by the implementation of a risk management plan 
(RMP) [34]. The findings for the infusion medications 
were mostly consistent with the listed side effects 
except for Novantrone. Its most common listed side 
effects include nausea and hair thinning, yet our 
findings show skin rash/reactions to account for 75% 
of discussed ADEs. It is important to note that the risk 




the decision for its potential use [35].  Together with a 
recent discontinuation of the brand-name medication 
and its availability under the generic name 
mitoxantrone , this may explain the data limitation 
[36].  
Most MS patients will initially be on first-line 
injectable treatments, which tend to have mild and 
manageable ADEs. [37]. However, the effectiveness 
of such medications and the patient’s tolerance of the 
side effects may warrant a  switch to other treatments 
[10]. Based on the course of MS and individual 
patient’s response, second-line or third-line 
medications may be selected. The ADEs identified in 
this study for each treatment is consistent with the 
National Multiple Sclerosis Society’s comparisons of 
different drugs and their ADEs [38].  
This study emphasizes the significance of further 
adoption of text mining techniques for detecting 
adverse drug events. Multiple sclerosis is not common 
but is a serious cause of neurological disability 
throughout adult life. Its prevalence has seen a marked 
increase since 1990 [39]. From a practical standpoint, 
automatically analyzing social media users posting 
with machine learning techniques will provide the 
medical community with valuable insights on patients’ 
behavior and reaction towards ADEs, symptoms, and 
treatments associated with MS. These may aid in 
recognizing the current state of MS treatments and the 
ADEs associated with it and can improve healthcare 
providers' understanding of the commonness of a 
particular ADE associated with an MS treatment as 
reported by patients.  
6. Conclusion  
This research focused on the ADEs of MS 
treatments from user-contributed contents on social 
media. The sentiment analysis and categorization of 
ADEs for various MS treatments indicate that the 
discussed side effects for injectable medications 
(Interferon-beta (Avonex, Betaseron, Extavia, 
Plegridy and Rebif), and Copaxone) are slightly higher 
when compared to infusion or oral medications. The 
underlying reasons for patients’ dislike of injectable 
medications are the side effects caused by the injection 
itself (frequent use of needles, injection-site reactions, 
and rashes). Furthermore, there is a noticeable 
excitement for new treatments such as Vumerity, 
Mavenclad, and Mayzent. Overall, the results shed 
light on the safety and effectiveness of drugs used for 
MS treatment and complement other post-marketing 
surveillance conducted through centralized 
volunteering reporting systems by relying on a 
relatively broader and timely user-contributed data. 
The results and recommendations of this study can 
help patients and clinicians identify appropriate 
courses of action and can inform future medical 
research by highlighting and prioritizing additional 
clinical trials needed to better understand such adverse 
drug effects. 
Some limitations of this study include constraints 
related to the data, namely, language (English), data 
source (Twitter), and analytics techniques. Twitter 
data might not reflect the actual patient population. 
According to Wojcik and Hughes [40], Twitter users 
tend to be a much younger audience, with 10% of users 
creating 80% of all tweets published. Future research 
may consider expanding to other languages and social 
media platforms such as health-related forums, Reddit, 
and Facebook. While CH provides extensive analytic 
and visualization capabilities, it may be limiting with 
respect to the diversity and complexity of the available 
techniques. For example, other machine learning such 
as topic mining coupled with thematic content analysis 
based on demographics and ADE type may shed 
further insights regarding the ADEs of various MS 
treatments.   
MS, a progressive degenerative disease of the 
central nervous system, has yet no cure. Current 
treatment options aim to reduce the contributory 
immune system’s attacks thereby reducing the number 
of relapses and slowing the progression of disability. 
Different oral, injectable, and infusion drugs for the 
disease are available with more drugs being introduced 
to the market. As MS treatment is long-term, ADEs 
present a challenge that affects the choice of drugs and 
the decision to remain on a given drug or change to 
another. As a result, the thorough understanding of 
these ADEs will be an ongoing endeavor. 
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